Latest Oncotype DX Stories
REDWOOD CITY, Calif., May 29, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June: Kim Popovits, Genomic Health's Chairman, Chief Executive Officer and President, will present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 4:00 p.m. ET in New York City; and Dean Schorno, Genomic Health's Chief Financial Officer, will present at the Goldman Sachs 33rd...
REDWOOD CITY, Calif., May 16, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from 18 separate studies covering breast, colon and prostate cancers will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, reflecting the company's ongoing commitment to the research, development and delivery of innovative diagnostic tests to help individualize cancer treatment decisions. The annual meeting is taking place June 1-5,...
Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy. The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most...
REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Genomic Health's Chief Operating Officer, will present the 11th Annual JMP Securities Research Conference in San Francisco on Tuesday, May 15 at 10:30 a.m. Pacific Time (PT). To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com. Please connect...
REDWOOD CITY, Calif., May 2, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and OncoMed Pharmaceuticals, Inc. (OncoMed) today announced a strategic alliance to use Next Generation Sequencing (NGS) to identify biomarkers that can be applied to the clinical development of OncoMed's novel antibody cancer therapeutics. Under the terms of the agreement, OncoMed will provide Genomic Health with breast, prostate, colon and lung tumor samples. A subset of these tumors will...
REDWOOD CITY, Calif., May 2, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2012. Total revenue increased to $58.5 million in the first quarter of 2012, compared with $49.8 million in 2011, an increase of 17 percent. Product revenue was $57.9 million in the first quarter of 2012, compared with $49.5 million for the same period in 2011, an increase of 17 percent. Contract...
REDWOOD CITY, Calif., April 25, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2012 financial results. The call and webcast will follow the release of the first quarter financial results after market close. Conference Call Details To access the live conference call on May 2 at 4:30 p.m. Eastern Time via phone, please dial...
Even after chemotherapy dose adjustment Women who are overweight or obese when they are diagnosed with breast cancer are at higher risk of cancer recurrence or related death than are leaner women, according to a new study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Friday). This finding held true even though the study mandated that chemotherapy dosage be adjusted for body weight, and adds further to the evidence that lifestyle factors can influence cancer...
Testing a breast cancer tumor for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Thursday). Dr. Sabine Linn, an Associate Professor of Medical Oncology at The Netherlands Cancer Institute, Amsterdam, The Netherlands, will say that this is the...
IRVINE, Calif. and AMSTERDAM, March 22, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that five-year follow-up data from the RASTER observational study indicates that its MammaPrint prognostic assay for breast cancer can help reduce adjuvant chemotherapy by 20 percent in patients deemed 'Low Risk.' From 2004 to 2006, the MircoarRAy PrognoSTics in Breast CancER study, known as RASTER, enrolled 427 women with primary breast...
